🇮🇳·15h agoIndustry
natco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26
Publisher
N
Natco Pharma
India
This page provides publisher metadata, and related coverage to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Natco Pharma
- Region
- India
- Scope
- Industry
- Published
- September 10, 2026
Publisher context, original article off-platform
This page presents the title, publisher metadata, and related coverage. The publisher did not provide a public summary in this feed. Full-text reading stays on the publisher's original site.
Source route
Continue on natcopharma.co.in
Leave the platform to read the original full article on the publisher site.
Source: Natco Pharma
Scope: Industry
Related coverage
More related coverage
Chugai Pharmaceutical News/6h ago
エンスプリングに関するロシュ社の発表について（MOG抗体関連疾患に対するFDAによる申請受理および優先審査指定）
Chugai Pharmaceutical/6h ago
Roche Announces U.S. FDA Grants Priority Review for Enspryng for Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
Ipsen/6h ago
Why evidence matters: Seema Meloni on making data meaningful
Ipsen RSS/6h ago